Insight Molecular Diagnostics Inc.
Business
Insight Molecular Diagnostics (iMDx) is a diagnostics technology company developing decentralized molecular diagnostic test kits for organ transplant rejection monitoring and oncology applications. The company offers laboratory-developed tests (LDTs) performed at its CLIA-certified Tennessee laboratory, research-use-only (RUO) kitted tests, and in vitro diagnostic (IVD) kitted tests for clinical use, with its flagship GraftAssure family quantifying donor-derived cell-free DNA (dd-cfDNA) as a transplant rejection biomarker. iMDx serves hospitals, transplant centers, research institutions, and clinical laboratories through direct relationships with physicians and lab directors, with geographic focus on the United States and European Union regulatory markets.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net revenue | 4 | 2 | 2 | 958,000 | 2 | |
| Cost of revenues | 2 | 1 | 1 | 880,000 | 697,000 | |
| Cost of revenues amortization of acquired intangibles | 7,000 | 88,000 | 88,000 | 96,000 | 81,000 | |
| Gross profit | 2 | 740,000 | 413,000 | −18,000 | 1 | |
| Research and development | 16 | 10 | 9 | 7 | 5 | |
| Sales and marketing | 6 | 4 | 3 | 1 | 552,000 | |
| General and administrative | 11 | 10 | 11 | 22 | 22 | |
| Change in fair value of contingent consideration | 6 | −4 | −6 | −31 | 27 | |
| Impairment losses | 15 | 42 | 7 | — | — | |
| Impairment loss on held for sale assets | 0 | 169,000 | 1 | — | — | |
| Total operating expenses | 53 | 62 | 26 | 18 | 55 | |
| Loss from operations | −51 | −61 | −25 | −18 | −54 | |
| Interest expense | −109,000 | −84,000 | −52,000 | −83,000 | −209,000 | |
| Other income, net | 1 | 462,000 | 394,000 | −61,000 | −37,000 | |
| Total other income, net | 902,000 | 378,000 | 281,000 | −615,000 | 854,000 | |
| Loss before income taxes | −50 | −61 | −25 | −19 | −44 | |
| Income taxes | 0 | 0 | — | — | 9 | |
| Net loss | −50 | −61 | −28 | −73 | −64 | |
| Net loss attributable to common stockholders - basic | −50 | −61 | −29 | −73 | −64 | |
| Net loss attributable to common stockholders - diluted | −50 | −61 | −29 | — | — | |
| Net loss attributable to common stockholders per share - basic | −1.65 | −4.66 | −3.75 | −13.25 | −0.72 | |
| Net loss attributable to common stockholders per share - diluted | −1.65 | −4.66 | −3.75 | −13.25 | — | |
| Weighted average shares outstanding - basic | 30 | 13 | 8 | 6 | 88,920 | |
| Weighted average shares outstanding - diluted | 30 | 13 | 8 | 6 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 12 | 9 | 9 | 20 | 33 | |
| Accounts receivable, net of allowance for credit losses of $11 and $16, respectively | 1 | 2 | 484,000 | 2 | 1 | |
| Inventories | 446,000 | 410,000 | — | — | — | |
| Deferred financing costs | 0 | 279,000 | — | — | — | |
| Restricted cash, current | 729,000 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 1 | 821,000 | 643,000 | 977,000 | 901,000 | |
| Total current assets | 15 | 12 | 11 | 26 | 39 | |
| Right-of-use operating and financing lease assets, net | 3 | 3 | — | — | — | |
| Machinery and equipment, net, and construction in progress | 6 | 4 | 4 | 9 | 6 | |
| Intangible assets, net | 0 | 15 | 57 | 62 | 62 | |
| Restricted cash, noncurrent | 607,000 | 2 | 2 | 2 | 2 | |
| Other noncurrent assets | 593,000 | 691,000 | 463,000 | 371,000 | 264,000 | |
| TOTAL ASSETS | 26 | 35 | 75 | 100 | 160 | |
| Accounts payable | 3 | 2 | 953,000 | 1 | 2 | |
| Due to related party (Note 9) | 3 | 638,000 | — | — | — | |
| Accrued compensation | 2 | 2 | 2 | 2 | 3 | |
| Accrued royalties | 1 | 1 | 1 | 2 | — | |
| Accrued expenses and other current liabilities | 939,000 | 418,000 | 452,000 | 2 | 2 | |
| Operating and financing lease liabilities, current | 2 | 1 | — | — | — | |
| Contingent consideration liabilities, current | 428,000 | 228,000 | 2 | 109,000 | 1 | |
| Total current liabilities | 12 | 7 | 7 | 12 | 14 | |
| Operating and financing lease liabilities, noncurrent | 2 | 2 | — | — | — | |
| Contingent consideration liabilities, noncurrent | 43 | 38 | 40 | 46 | 77 | |
| TOTAL LIABILITIES | 57 | 47 | 49 | 60 | 94 | |
| Commitments and contingencies (Note 6) | — | — | — | — | — | |
| Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding | 0 | 0 | — | — | — | |
| Common stock, no par value, 230,000 shares authorized; 28,683 and 17,453 shares issued and outstanding at December 31, 2025 and 2024, respectively | 369 | 338 | 310 | 295 | 253 | |
| Accumulated other comprehensive income | 86,000 | 21,000 | 49,000 | 39,000 | 37,000 | |
| Accumulated deficit | −401 | −351 | −290 | 1 | −188 | |
| Total shareholders' deficit | −31 | −12 | 20 | 34 | 65 | |
| TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT | 26 | 35 | 75 | 100 | 160 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization expense | 2 | 2 | 2 | 2 | — | |
| Amortization of intangible assets | 7,000 | 88,000 | 88,000 | 4 | 3 | |
| Stock-based compensation | 2 | 2 | 3 | 10 | 7 | |
| Equity compensation for bonus awards and consulting services | 164,000 | 160,000 | 127,000 | — | — | |
| Impairment loss on held for sale assets | 0 | 169,000 | 1 | — | — | |
| Unrealized foreign currency losses (gains) | 185,000 | −4,000 | — | — | — | |
| Accounts receivable | 485,000 | −1 | 109,000 | −575,000 | −1 | |
| Inventories | −36,000 | −410,000 | — | — | — | |
| Prepaid expenses and other assets | −226,000 | −430,000 | 784,000 | −231,000 | 227,000 | |
| Accounts payable and accrued liabilities | 3 | 967,000 | −5 | 297,000 | −1 | |
| Operating lease assets and liabilities | −142,000 | −291,000 | −107,000 | −116,000 | 147,000 | |
| Net cash used in operating activities | −22 | −21 | −23 | −46 | −36 | |
| Proceeds from sale of equipment | 0 | 4,000 | 354,000 | — | — | |
| Machinery and equipment purchases, and construction in progress | −3 | −516,000 | −281,000 | −4 | −2 | |
| Net cash used in investing activities | −3 | −512,000 | −932,000 | −4 | −14 | |
| Proceeds from sale of common shares | 29 | 26 | 14 | 33 | 65 | |
| Financing costs to issue common shares | −487,000 | −1 | −427,000 | −389,000 | −3 | |
| Proceeds from sale of common shares under at-the-market transactions | 0 | 2 | — | 31,000 | — | |
| Financing costs for at-the-market sales | 0 | −421,000 | — | −1,000 | — | |
| Redemption of Series A redeemable convertible preferred shares | 0 | −5 | −1 | — | — | |
| Contingent consideration liability payments | −2,000 | 0 | — | — | — | |
| Taxes paid related to net share settlement of stock-based awards | −72,000 | 0 | — | — | — | |
| Repayment of financing lease obligations | −510,000 | −201,000 | −117,000 | −104,000 | −34,000 | |
| Net provided by financing activities | 28 | 20 | 12 | 36 | 78 | |
| Effect of exchange rate changes on cash and cash equivalents | −120,000 | −24,000 | — | — | — | |
| NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 3 | −796,000 | −12 | −14 | 28 | |
| Cash paid for interest | 91,000 | 42,000 | 7,000 | 24,000 | 114,000 | |
| Cash paid for income taxes | 0 | 0 | — | — | — | |
| Machinery and equipment purchases, and construction in progress included in accounts payable and accrued liabilities | 1 | 570,000 | — | — | — | |
| Accretion of Series A convertible preferred stock | 0 | 263,000 | 824,000 | — | — | |
| Lease assets obtained in exchange for lease liabilities | 1 | 2 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Insight Molecular Diagnostics Inc.'s CIK number?
Insight Molecular Diagnostics Inc.'s SEC CIK number is 0001642380 (1642380). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Insight Molecular Diagnostics Inc.'s SEC filings?
All of Insight Molecular Diagnostics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Insight Molecular Diagnostics Inc. last report earnings?
Insight Molecular Diagnostics Inc. (IMDX) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-022721). This is Insight Molecular Diagnostics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Insight Molecular Diagnostics Inc.'s most recent earnings 8-K?
Insight Molecular Diagnostics Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001493152-26-022721. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Insight Molecular Diagnostics Inc.'s latest earnings 8-K →
Look up any company's CIK number →